Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

BACKGROUND. Antitumor activity of the combination of somatostatin analogues (SSAs) and the mammalian target of rapamycin (mTOR) inhibitor everolimus in patients with neuroendocrine tumors (NETs) has been reported but not confirmed in prospective trials. MATERIALS AND METHODS. This prospective, multi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Capdevila, Jaume, Teulé, Alexandre, Barriuso, Jorge, Castellano, Daniel, Lopez, Carlos, Manzano, Jose Luis, Alonso, Vicente, García‐Carbonero, Rocío, Dotor, Emma, Matos, Ignacio, Custodio, Ana, Casanovas, Oriol, Salazar, Ramon
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Endocrinology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324631/
https://ncbi.nlm.nih.gov/pubmed/29794066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0622
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados